Buehlmann



GanglioCombi-GM

… the expert’s choice: for acute/chronic screening

test

GanglioCombi-GM is provides the 6 clinically most relevant gangliosides, GM1, asialo-GM1 (GA1), GM2, GD1a, GD1b and GQ1b. IgG anti-ganglioside antibodies are usually associated with acute neuropathies whereas IgM anti-ganglioside antibodies are associated with chronic neuropathies.

 

 


The set-up and Lay-out are presented in Fig 1a and 1b.

Fig 1a

Fig 1b

Product Information

GanglioCOMBI-GM

Method

ELISA

Time to results

4.5 h

Sample Type

20 µl serum (1:50)

Standard range

quantitative

Isotypes

IgG and gM

Order code

EK-GCO-GM 2x12 profiles
CE

DOWNLOADS

Instruction
for use*

GanglioCombi-GM

Clinical Information

Technical Information

English  

[PDF 0.3MB] [PDF 0.3MB] -

Deutsch

[PDF 0.3MB] -

Francais

- -

Italiano

- -

* Multilingual document [EN, DE, FR, IT, ES]

Contact

BÜHLMANN Laboratories AG
Baselstr. 55
CH-4124 Schönenbuch
Switzerland
Fon: +41 61 487 12 12
Fax: +41 61 487 12 34
info@buhlmannlabs.ch

Your local distributor
Order
About us
Job opportunities

News

NEW OWN CALPROTECTIN REIMBURSEMENT POSITION IN SWITZERLAND

BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1st 2012, has an official new position in the reimb  more

New Seegene DPO Movie showing how this unique and proprietary technology is working to allow innovative multiplexing.

The unique and proprietary DPO™(Dual-Priming-Oligonucleotide) technology is the corner stone for all of the Seegene products, and it is the key to achieve  more

New EntroGen BRAF test (V600E/K/D) for the detection of important mutations found in melanoma on your real-time PCR instrument.

EntroGen has a new BRAF test that detects, beside the V600E mutation, also the V600K and the V600D, which are important mutations found in melanoma.   more

BÜHLMANN innovations and news at the JIB

At the JIB Congress in Paris, 8th – 10th November 2011, BÜHLMANN presents the MDx products of EntroGen and AutoGenomics as well as new developments of its  more

Get our RSS - Feed